(Q37109351)

18 August 2017

1 reference

title

Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain (English)

1 reference

18 August 2017

1 reference

6

Lieuwe de Haan

1 reference

18 August 2017

Jamie Karagianis

1

1 reference

18 August 2017

Vicki Poole Hoffmann

2

1 reference

18 August 2017

Belen Arranz

3

1 reference

18 August 2017

Tamás Treuer

4

1 reference

18 August 2017

Gerald A Maguire

5

1 reference

18 August 2017

Bharat Chawla

7

1 reference

18 August 2017

publication date

1 June 2008

1 reference

18 August 2017

published in

Human Psychopharmacology

1 reference

18 August 2017

volume

23

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

275-281

1 reference

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

18 August 2017

cites work

1 reference

Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.

21 January 2018

1 reference

7 January 2021

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone

1 reference

7 January 2021

Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets

1 reference

7 January 2021

Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets

1 reference

7 January 2021

Serotonin contracts the isolated rat pylorus via a 5-HT2-like receptor

1 reference

7 January 2021

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine

1 reference

7 January 2021

Wellness intervention for patients with serious and persistent mental illness.

1 reference

7 January 2021

Advances in psychotropic formulations

1 reference

7 January 2021

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

1 reference

7 January 2021

Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia

1 reference

7 January 2021

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

1 reference

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

7 January 2021

The Effects of an Educational Intervention on Antipsychotic‐Induced Weight Gain

1 reference

7 January 2021

Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers

1 reference

7 January 2021

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

1 reference

7 January 2021

Reversal of antipsychotic-associated weight gain.

1 reference

7 January 2021

Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home

1 reference

7 January 2021

Long-term treatment with atypical antipsychotics and risk of weight gain

1 reference

7 January 2021

A program for managing weight gain associated with atypical antipsychotics.

1 reference

7 January 2021

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

1 reference

7 January 2021

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.933

1 reference

release_xc72lsiaabdmzoncgnii4zsw24

18 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xc72lsiaabdmzoncgnii4zsw24

24 November 2022

mapped directly with Wikidata item

1 reference